Picture of Evotec SE logo

EVT — Evotec SE News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapNeutral

Brief: Evotec Introduces New Phased 2026-2030 Mid-Term Framework, Aligned With Transformation Roadmap

March 10 (Reuters) - EVOTEC SE EVTG.DE:

FY D&PD SEGMENT REVENUE EUR 529 MILLION VERSUS. IBES ESTIMATE EUR 834.4 MILLION

FY 2025 ADJUSTED EBITDA EUR 41 MILLION

FY REVENUE EUR 788 MILLION VERSUS. IBES ESTIMATE EUR 778.9 MILLION

FY ADJUSTED EBITDA EUR 41 MILLION

STRUCTURAL HORIZON MEASURES EXPECTED TO GENERATE AROUND EUR 75 MILLION RUN-RATE SAVINGS BY END OF 2027

NEW PHASED 2026-2030 MID-TERM FRAMEWORK INTRODUCED, ALIGNED WITH TRANSFORMATION ROADMAP

OUTLOOK 2026: GROUP REVENUES OF APPROXIMATELY EUR 700-780 MILLION

OUTLOOK 2026: ADJUSTED GROUP EBITDA OF APPROXIMATELY EUR 0-40 MILLION

OUTLOOK MID-TERM: GROUP REVENUES ARE EXPECTED TO GROW TO > EUR 1 BILLION

ADJUSTED MID-TERM EBITDA MARGIN SEEN TO REACH 20% BY 2028 AND EXCEED THAT LEVEL BY 2030

Further company coverage: EVTG.DE

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Evotec SE

See all news